Abstract

The World Health Organisation (WHO) has recently revised how adverse events after immunization (AEFI) are classified. Only reactions that have previously been acknowledged in epidemiological studies to be caused by the vaccine are classified as a vaccine-product–related-reaction. Deaths observed during post-marketing surveillance are not considered as ‘consistent with causal association with vaccine’, if there was no statistically significant increase in deaths recorded during the small Phase 3 trials that preceded it. Of course, vaccines noted to have caused a significant increase in deaths in the control-trials stage would probably not be licensed. After licensure, deaths and all new serious adverse reactions are labelled as ‘coincidental deaths/events’ or ‘unclassifiable’, and the association with vaccine is not acknowledged. The resulting paradox is evident. The definition of causal association has also been changed. It is now used only if there is ‘no other factor intervening in the processes’. Therefore, if a child with an underlying congenital heart disease (other factor), develops fever and cardiac decompensation after vaccination, the cardiac failure would not be considered causally related to the vaccine. The Global Advisory Committee on Vaccine Safety has documented many deaths in children with pre-existing heart disease after they were administered the pentavalent vaccine. The WHO now advises precautions when vaccinating such children. This has reduced the risk of death. Using the new definition of causal association, this relationship would not be acknowledged and lives would be put at risk. In view of the above, it is necessary that the AEFI manual be revaluated and revised urgently. AEFI reporting is said to be for vaccine safety. Child safety (safety of children) rather than vaccine safety (safety for vaccines) needs to be the emphasis.

Highlights

  • One of the earliest countries to introduce the pentavalent vaccine was Sri Lanka[1]

  • The World Health Organization (WHO) experts investigated the Vietnam deaths. This time they reported, ‘Quinvaxem was pre-qualified by WHO..., no fatal adverse event following immunisation (AEFI) has ever been associated with this vaccine’[5]. This is the same brand of pentavalent vaccine that was used in Sri Lanka where WHO experts had previously documented adverse events following immunization (AEFI) deaths

  • Any hypothesis of why there would be a two-fold difference in SIDS (?) mortality? Did the patterns differ for boys and girls? We have found that DTP and pentavalent vaccine (Penta) are both associated with much higher female-than-male all-cause mortality rates 7,12

Read more

Summary

28 Feb 2018 report report

Any reports and responses or comments on the article can be found at the end of the article. Keywords Pentavalent vaccine; quinvaxim; pharmacovigilance; Hill criteria; macrophagicmyofasciitis; periodic safety update reports; Brighton classification; adverse drug reactions; sudden unexpected death; TOKEN study. 3. T he Bradford Hill criteria introduced and Bradford Hill’s biological gradient is discussed in the context of the harms of using multiple antigens all together. 4. A lso the limitation of current knowledge (biological plausibility) delaying the acknowledgement of deaths in girls with high dose measles has been introduced. 7. T he matter of the difference in death rates in boys and girls with high potency measles vaccine for which there is yet no scientifically plausible explanation has been added. 8. A new paragraph on the mechanism of deaths after multiple vaccines related a cytokine storm (and deaths in susceptible babies) as held in a court ruling was added. M ention has been made of the efforts made to get the WHO to respond to the points made here

Introduction
Section B Brighton Abandoned
WHO Experts Report
11. Center for Disease Control and Prevention
26. Sci Dev Net
Conclusion
Page 10
Abbreviation PV has been removed
Findings
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.